Gilbert Technologies

Gilbert is developing the next-generation soft mist inhaler using proprietary electrohydrodynamic atomization (EHDA) technology, enabling precise, customizable delivery of advanced pharmaceutical compounds directly to the lungs. The company is not yet in clinical trials but is progressing toward clinical-stage development, with a focus on improving inhaled treatments for difficult-to-treat lung conditions, including anti-infectives, biologics, and potentially oncolytics. The technology promises targeted, monodisperse aerosol delivery, which could improve patient outcomes, reduce systemic side effects, and decrease healthcare costs compared to existing inhalers. The company has achieved ISO 13485:2016 certification, validating its quality management system for medical devices, and has raised €7 million in funding (Seed and Series A) to advance its platform and partnerships.